Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Ovarian Neoplasms × Tyrosine Kinase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 3 Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thoracic Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Pleural Neoplasms 1 Pleural Effusion, Malignant 1 Pleural Effusion 1 Pleural Diseases 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Lung Neoplasms 1 Lung Diseases 1 Leukemia, Myeloid, Chronic-Phase 1 Kidney Neoplasms 1 Gastro Intestinal Stromal Tumor 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma, Bronchogenic 1

Interventions

Paclitaxel 80 Carboplatin 76 Bevacizumab 53 Gemcitabine 29 pembrolizumab 27 liposomal doxorubicin 27 Topotecan 22 olaparib 19 Taxes 17 niraparib 15 Docetaxel 15 Immunoglobulin G 14 Disulfides 14 Cyclophosphamide 14 Cisplatin 11 durvalumab 10 Nivolumab 9 Doxorubicin 8 Albumin-Bound Paclitaxel 8 sargramostim 7 rucaparib 7 fludarabine phosphate 7 fludarabine 7 pazopanib 6 epacadostat 6 avelumab 6 Trabectedin 6 Magnetic Resonance Spectroscopy 6 Ipilimumab 6 Interleukin-2 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡